| 產品名稱 | MDA-MB-231 |
|---|---|
| 商品貨號 | B228845 |
| Organism | Homo sapiens, human |
| Tissue | mammary gland/breast; derived from metastatic site: pleural effusion |
| Cell Type | epithelial cell (KRAS CRM) |
| Product Format | frozen |
| Morphology | epithelial |
| Culture Properties | adherent |
| Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | adenocarcinoma |
| Age | 51 years adult |
| Gender | female |
| Ethnicity | Caucasian |
| Applications | For use in testing and calibration in ISO 17025 accredited laboratories, to challenge assay performance, validate or compare test methods, and to establish sensitivity, linearity and specificity during assay validation or implementation. This cell line may be used as a transfection host. |
| Intended Use | Certified Reference Material produced under an ISO 17034 accredited process.
|
| Storage Conditions | liquid nitrogen vapor phase |
| Karyotype | The cell line is aneuploid female (modal number = 64, range = 52 to 68), with chromosome counts in the near-triploid range. Normal chromosomes N8 and N15 were absent. Eleven stable rearranged marker chromosomes are noted as well as unassignable chromosomes in addition to the majority of autosomes that are trisomic. Many of the marker chromosomes are identical to those shown in the karyotype reported by K.L. Satya-Prakash, et al. |
| Receptor Expression | epidermal growth factor (EGF), expressed transforming growth factor alpha (TGF alpha), expressed |
| Tumorigenic | Yes |
| Effects | Yes, in ALS treated BALB/c mice, forms poorly differentiated adenocarcinoma (grade III) Yes, in nude mice, forms poorly differentiated adenocarcinoma (grade III) |
| Comments | Certificates of Analysis are available electronically at www.atcc.org, or by hardcopy upon request. Certified Reference Material produced under an ISO 17034 accredited process.
Item has been tested for KRAS mutation (p.G13D c.38G>A) The cells express the WNT7B oncogene [PubMed: 8168088]. |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated Leibovitz's L-15 Medium, Catalog No. 30-2008. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. (Note: The L-15 medium formulation was devised for use in a free gas exchange with atmospheric air. A CO2 and air mixture is detrimental to cells when using this medium for cultivation) |
| Subculturing |
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended
Medium Renewal: 2 to 3 times per week |
| Cryopreservation | Freeze Medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage Temperature: Liquid nitrogen vapor phase |
| Culture Conditions | Atmosphere: air, 100%
Temperature: 37°C |
| STR Profile | Amelogenin: X CSF1PO: 12,13 D13S317: 13 D16S539: 12 D5S818: 12 D7S820: 8,9 THO1: 7,9.3 TPOX: 8,9 vWA: 15,18 |
| Isoenzymes | AK-1, 1 ES-D, 1 G6PD, B GLO-I, 2 Me-2, 1-2 PGM1, 1-2 PGM3, 1 |
| Name of Depositor | R Cailleau |
| Deposited As | Homo sapiens |
| References | Brinkley BR, et al. Variations in cell form and cytoskeleton in human breast carcinoma cells in vitro. Cancer Res. 40: 3118-3129, 1980. PubMed: 7000337 Cruciger Q, et al. Morphological, biochemical and chromosomal characterization of breast tumor lines from pleural effusions. In Vitro 12: 331, 1976. Siciliano MJ, et al. Mutually exclusive genetic signatures of human breast tumor cell lines with a common chromosomal marker. Cancer Res. 39: 919-922, 1979. PubMed: 427779 Cailleau R, et al. Breast tumor cell lines from pleural effusions. J. Natl. Cancer Inst. 53: 661-674, 1974. PubMed: 4412247 Cailleau R, et al. Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro 14: 911-915, 1978. PubMed: 730202 Bates SE, et al. Expression of the transforming growth factor-alpha/epidermal growth factor receptor pathway in normal human breast epithelial cells. Endocrinology 126: 596-607, 1990. PubMed: 2294006 Dickstein B, et al. Increased epidermal growth factor receptor in an estrogen-responsive, adriamycin-resistant MCF-7 cell line. J. Cell. Physiol. 157: 110-118, 1993. PubMed: 8408230 Huguet EL, et al. Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res. 54: 2615-2621, 1994. PubMed: 8168088 Satya-Prakash KL, et al. Cytogenetic analysis on eight human breast tumor cell lines: high frequencies of 1q, 11q and HeLa-like marker chromosomes. Cancer Genet. Cytogenet. 3: 61-73, 1981. PubMed: 7272986 Katayose Y, et al. Promoting apoptosis: a novel activity associated with the Cyclin-dependent kinase inhibitor p27. Cancer Res. 57: 5441-5445, 1997. PubMed: 9407946 Littlewood-Evans AJ, et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res. 57: 5386-5390, 1997. PubMed: 9393764 Sheng S, et al. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc. Natl. Acad. Sci. USA 93: 11669-11674, 1996. PubMed: 8876194 De Vincenzo R, et al. Antiproliferative activity of colchicine analogues on MDR-positive and MDR-negative human cancer cell lines. Anticancer Drug Des. 13: 19-33, 1998. PubMed: 9474240 Soker S, et al. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-endoded domain. J. Biol. Chem. 271: 5761-5767, 1996. PubMed: 8621443 |
| 梅經理 | 17280875617 | 1438578920 |
| 胡經理 | 13345964880 | 2438244627 |
| 周經理 | 17757487661 | 1296385441 |
| 于經理 | 18067160830 | 2088210172 |
| 沈經理 | 19548299266 | 2662369050 |
| 李經理 | 13626845108 | 972239479 |
